midazolam has been researched along with Renal Insufficiency, Chronic in 3 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam AUC was significantly higher in the HD group (382." | 1.42 | Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ( Asher, LJ; Feere, DA; House, AA; Knauer, MJ; Nolin, TD; Thomson, BK; Urquhart, BL; Velenosi, TJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tokunaga, A | 1 |
| Miyamoto, H | 1 |
| Fumoto, S | 1 |
| Nishida, K | 2 |
| Watanabe, H | 1 |
| Sugimoto, R | 1 |
| Ikegami, K | 1 |
| Enoki, Y | 1 |
| Imafuku, T | 1 |
| Fujimura, R | 1 |
| Bi, J | 1 |
| Sakaguchi, Y | 1 |
| Murata, M | 1 |
| Maeda, H | 1 |
| Hirata, K | 1 |
| Jingami, S | 1 |
| Ishima, Y | 1 |
| Tanaka, M | 1 |
| Matsushita, K | 1 |
| Komaba, H | 1 |
| Fukagawa, M | 1 |
| Otagiri, M | 1 |
| Maruyama, T | 1 |
| Thomson, BK | 1 |
| Nolin, TD | 1 |
| Velenosi, TJ | 1 |
| Feere, DA | 1 |
| Knauer, MJ | 1 |
| Asher, LJ | 1 |
| House, AA | 1 |
| Urquhart, BL | 1 |
3 other studies available for midazolam and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Effect of Chronic Kidney Disease on Hepatic Clearance of Drugs in Rats.
Topics: Acetaminophen; Adenine; Administration, Intravenous; Animals; Cytochrome P-450 CYP3A; Disease Models | 2020 |
Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.
Topics: Animals; Caco-2 Cells; Cinacalcet; Cyclic AMP; Cytochrome P-450 CYP3A; Down-Regulation; GABA Modulat | 2017 |
Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Anti-Anxiety Agents; Cytochrome P-450 CYP3A; F | 2015 |